Skip to main content
. 2022 Dec 12;2022:6987806. doi: 10.1155/2022/6987806

Table 10.

The evaluation of the anticancer properties of ligand (HL) and its complexes (1a-2a) against cancer cell lines and normal cell lines.

Compounds IC50 (μM)
A549 HepG2 MCF-7 NHDF
Cisplatin 31.9 ± 1.6 22.9 ± 1.1 20.2 ± 1.0 26.9 ± 1.3
(HL) 126.4 ± 6.3 108.4 ± 5.4 105.2 ± 5.3 208.6 ± 10.4
(1a) 30.8 ± 1.5 33.1 ± 1.7 32.1 ± 1.6 73.6 ± 3.7
(2a) 34.3 ± 1.7 34.6 ± 1.7 35.6 ± 1.8 78.4 ± 3.9